Invivyd, Inc.

Stage 1 · Basing · week 4

As of Oct 22, 2026, Invivyd is in Stage 1, the basing phase, now in week 4 (since Sep 30, 2026). It closed at $0.61, 78.8% below its 52-week high and below its 200-day average, which is falling.

$0.61

-7.29% today

$180M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is IVVD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 14w

S4 37w

S2 22w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 8w → S3 6w → S2 14w → S3 9w → S4 37w → S1 6w → S2 3w → S3 1w → S4 6w → S1 6w → S2 3w → S3 1w → S4 3w → S3 1w → S2 22w → S3 9w → S4 24w → S1 3w current

Total tracked: 166 weeks across 19 stage runs.

IVVD among Biotechnology430th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…430	IVVDInvivyd, Inc.	Stage 1 · wk 4	15	−33.9%

vs 52W High

-78.8%

$0.54 lo$2.88 hi

78.8% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 4

1w13w26w

Week 4, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-50.0%

200 DMA: $1.22 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.78x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-33.9%

-0.2%

-59.6%

YTD

-75.6%

-70.1%

Scan Membership

Breakout Watch

Latest: 2025-03-26

3 appearances in last 60 days. First seen: 2023-09-15.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 4 · Vol 0.78x

2026-10-21S1

Wk 4 · Vol 1.08x

2026-10-20S1

Wk 3 · Vol 0.41x

2026-10-19S1

Wk 3 · Vol 0.82x

2026-10-16S1

Wk 3 · Vol 0.63x

2026-10-15S1

Wk 3 · Vol 0.60x

2026-10-14S1

Wk 3 · Vol 0.73x

2026-10-13S1

Wk 2 · Vol 0.67x

2026-10-12S1

Wk 2 · Vol 0.52x

2026-10-09S1

Wk 2 · Vol 0.51x

2026-10-08S1

Wk 2 · Vol 1.96x

2026-10-07S1

Wk 2 · Vol 1.82x

Moving averages & range

50 DMA

$0.81

200 DMA

$1.22

52W High

$2.88

52W Low

$0.54

5D Low

$0.61

Resistance levels (recent highs)

20d High

$0.95

60d High

$1.02

120d High

$1.51

250d High

$2.88

Next resistance

+55.7%

to 20d High

ROE

-95.9%

Profit margin -183.9%

Dividend Yield

0.00%

P/B 1.0

Invivyd: quick answers

What stage is Invivyd in?

As of Oct 22, 2026, Invivyd (IVVD) is in Stage 1, the basing phase. It entered Stage 1 on Sep 30, 2026 and is in week 4. What the four stages mean

Is Invivyd in an uptrend?

Not yet. Invivyd is in Stage 1, a base that can come before an uptrend. It trades 50.0% below its 200-day average, which is falling.

How far is Invivyd from its 52-week high?

Invivyd closed at $0.61 on Oct 22, 2026, 78.8% below its 52-week high of $2.88. Its 52-week low is $0.54.

How has Invivyd performed over the past year?

As of Oct 22, 2026, Invivyd is down 70.1% over the past year and down 75.6% so far in 2026.

Which sector and industry is Invivyd in?

Invivyd is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.